BMC Infectious Diseases 2012, 12:352/1471-2334/12/352
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines up...date the recommendations that were first released in 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
more
ECDC MISSION REPORT 19–21 September 2016 ; 14–15 November 2016
Regional action plan 2019-2023
Meeting Report
27–30 June 2017 Manila, Philippines
UNAIDS/99.31E (English original, June 1999)
1st revision, April 2000
October 2018
This publication was produced at the request of the United States Agency for International Development. It was prepared independently by David Lowe, David Hales, Britt Herstad, Billy Pick, Aisuluu Bolotbaeva, and Gulgun Jonboboeva.
PLOS ONE | https://doi.org/10.1371/journal.pone.0186835 October 30, 2017
Unofficial Translation
Approved by the Federal Government on October 20, 2016